Srinath (Sri) Thirumalairajan, Ph.D., Director of Process Engineering at Seagen, Inc., a global biotechnology company dedicated to revolutionizing cancer care, is an experienced Chemist with 13+ years of industrial experience and is well versed in the preparation of highly potent APIs (HPAPIs), bioconjugates, analytical method development/qualification, and the establishment and implementation of safe handling procedures HPAPI.
Prior to joining Seagen, Sri was Executive Director – Bioconjugation Chemistry and CGMP Manufacturing at NJ Bio where he was leading the company’s teams of bioconjugation, process development, and GMP manufacturing chemists. Prior to this, Sri held positions as Production Executive at Cipla Ltd. (India), as Research Scientist at Toronto Research Chemicals; as Principal Scientist at The Chemistry Research Solution LLC (TCRS); and – after TCRS’ acquisition by Abzena – as Associate Director, Director, and then Senior Director of GMP Manufacturing at Abzena, where he was responsible for the process development and cGMP manufacture of ADC constructs and HPAPIs.
Sri received his Ph.D. in Chemistry from the University of Leeds (U.K.) and then joined Dalhousie University (Canada) as a Post-Doctoral/Research Fellow to perform research studies in enzymology and the total synthesis of an anti-cancer natural product. He has co-authored a significant number of publications related to synthetic/medicinal chemistry in peer-reviewed journals and is a co-inventor on two patents related to novel ADC constructs.
